Chronic Spontaneous Urticaria and Bruton Tyrosine Kinase: A Multispecialty Expert Discussion - Episode 14
Key Takeaways and Considerations for the Use of BTK Inhibitors in CSU Treatment
Published on:
Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors represent a promising new therapeutic class for chronic spontaneous urticaria (CSU) by offering rapid symptom control through targeted inhibition of both mast cell and B cell pathways, with newer agents like remibrutinib showing high selectivity, favorable safety, and robust efficacy in clinical trials that could position them as an important oral therapy option between antihistamines and biologics.
Video content above is prompted by the following:
- What are some key takeaways on the potential use of BTK inhibitors in the treatment of CSU that you’d like to share with clinicians managing this condition?
